NASDAQ$JAZZ
Jazz Pharmaceuticals · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Jazz Pharmaceuticals announced its Q4 2023 financial results, demonstrating revenue growth and strategic pipeline advancements.
Jazz Pharmaceuticals reported a strong Q4 2023, achieving its first $1 billion revenue quarter, driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company's oncology revenue surpassed $1 billion in 2023, and they anticipate multiple late-stage pipeline catalysts in 2024.
- Achieved first $1 billion revenue quarter.
- Xywav net product sales increased 20% year-over-year in Q4 2023.
- Epidiolex/Epidyolex net product sales increased 16% year-over-year in Q4 2023.
- Rylaze net product sales increased 26% year-over-year in Q4 2023.
Headline financials
Revenue & EPS history
Jazz Pharmaceuticals · Revenue · Quarterly
$1.01B
Revenue by segment
Jazz Pharmaceuticals · $493M total across 4 segments · Q1 2020
- Xyrem$408M+10.7%82.8%
- Defitelio/defibrotide$47.4M+14.3%9.6%
- Vyxeos$32.7M+13.0%6.6%
- Royalties & Contract Revenue$4.52M-6.9%0.9%
Forward guidance
Jazz Pharmaceuticals provided full year 2024 financial guidance, expecting revenues between $4.0 and $4.2 billion. Neuroscience revenue is projected between $2.8 and $2.95 billion, and Oncology revenue between $1.12 and $1.22 billion.
Tailwinds
- Total revenue guidance of $4.0 to $4.2 billion.
- Neuroscience revenue guidance of $2.8 to $2.95 billion.
- Oncology revenue guidance of $1.12 to $1.22 billion.
- Non-GAAP gross margin % of 93%
- Non-GAAP net income between $1.275 and $1.350 billion
Headwinds
- GAAP Gross margin % of 89%
- GAAP SG&A expenses between $1.346 and $1.426 billion.
- GAAP R&D expenses between $877 and $935 million.
- GAAP Effective tax rate between (22)% and (3)%.
- Net income between $385 and $530 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.3%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+0.7%
Avg return
30 days after
52%
34 / 65 earnings
Positive
+13.4%
Q4 2025
Best reaction
-13.4%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +8.6% | +15.4% | |
| Q4 2025 | +13.4% | +9.6% | +5.1% | |
| Q3 2025 | -2.4% | -0.1% | +23.7% | |
| Q1 2025 | -8.6% | -6.8% | -0.0% | |
| Q4 2024 | +3.2% | +0.4% | -12.0% | |
| Q3 2024 | +6.9% | +14.1% | +10.0% | |
| Q2 2024 | +1.9% | -0.6% | +3.3% | |
| Q1 2024 | -1.3% | -0.8% | -5.0% | |
| Q4 2023 | -10.1% | -11.1% | -9.0% | |
| Q3 2023 | -12.8% | -8.7% | -9.9% | |
| Q2 2023 | +2.2% | +5.9% | +3.1% | |
| Q1 2023 | +1.2% | -0.6% | -6.2% | |
| Q4 2022 | +2.8% | +1.7% | +4.2% | |
| Q3 2022 | +5.1% | +4.1% | +6.5% | |
| Q2 2022 | -1.0% | +0.9% | +1.4% | |
| Q1 2022 | -1.9% | -9.2% | -2.9% | |
| Q4 2021 | +11.4% | +12.4% | +13.3% | |
| Q3 2021 | +2.3% | +4.7% | -7.7% | |
| Q2 2021 | -10.1% | -12.1% | -20.5% | |
| Q1 2021 | +3.4% | +5.7% | +5.0% | |
| Q4 2020 | +7.3% | +3.9% | +3.1% | |
| Q3 2020 | +3.2% | +3.2% | +0.3% | |
| Q2 2020 | +9.2% | +12.6% | +20.0% | |
| Q1 2020 | +4.2% | +1.6% | +12.1% | |
| Q4 2019 | -10.9% | -12.4% | -23.0% | |
| Q3 2019 | -1.0% | +1.2% | +15.1% | |
| Q2 2019 | +0.9% | +1.4% | -6.4% | |
| Q1 2019 | +5.9% | +4.8% | -3.0% | |
| Q4 2018 | +9.2% | +10.1% | +11.0% | |
| Q3 2018 | -13.4% | -10.2% | -11.5% | |
| Q2 2018 | -0.6% | -0.3% | -4.4% | |
| Q1 2018 | +6.3% | +11.8% | +19.4% | |
| Q4 2017 | -1.8% | -4.1% | +2.4% | |
| Q3 2017 | -2.7% | -1.1% | -3.9% | |
| Q2 2017 | -8.1% | -8.3% | -3.1% | |
| Q1 2017 | +0.1% | -1.8% | -1.4% | |
| Q4 2016 | -0.9% | -2.2% | +6.4% | |
| Q3 2016 | +4.7% | +5.2% | -5.3% | |
| Q2 2016 | -6.0% | -8.4% | -18.4% | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | -2.9% | — | — | |
| Q3 2015 | -4.5% | — | — | |
| Q2 2015 | -3.4% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +3.4% | — | — | |
| Q3 2014 | -1.8% | — | — | |
| Q2 2014 | +3.7% | — | — | |
| Q1 2014 | -5.8% | — | — | |
| Q4 2013 | -5.6% | — | — | |
| Q3 2013 | +3.5% | — | — | |
| Q2 2013 | +3.3% | — | — | |
| Q1 2013 | -7.1% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q3 2012 | +0.4% | — | — | |
| Q2 2012 | -4.9% | — | — | |
| Q1 2011 | -2.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q1 2010 | +3.8% | — | — | |
| Q4 2011 | +3.8% | — | — | |
| Q4 2009 | +3.8% | — | — | |
| Q3 2010 | -0.6% | — | — | |
| Q3 2011 | -0.6% | — | — | |
| Q2 2011 | -9.2% | — | — | |
| Q4 2010 | -9.2% | — | — | |
| Q2 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro